FDA flags rare blindness risk from GLP-1 drugs: How do they weigh risks against treatment benefits?
New Delhi, Nov. 20 -- GLP-1 medications such as semaglutide have brought a significant change in the way we treat type 2 diabetes and obesity. Many patients have reported improved blood sugar levels, significant weight loss, and reduced risk of certain cardiovascular conditions with these medications. But the recent announcement from the US Food and Drug Administration (FDA) of a possible association between these drugs and a rare eye condition has understandably made patients more wary.
Non-arteritic anterior ischemic optic neuropathy (NAION) is an ophthalmic disease that reduces blood flow to the optic nerve, leading to damage and impaired vision. This often results in sudden, painless vision loss, typically in one eye. This condition ...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.